United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $517.51, for a total value of $4,916,345.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,902,496.93. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Trading Down 1.0%

UTHR stock opened at $510.38 on Tuesday. United Therapeutics Corporation has a twelve month low of $303.08 and a twelve month high of $609.35. The company has a market capitalization of $21.89 billion, a P/E ratio of 18.26, a PEG ratio of 1.75 and a beta of 0.59. The firm has a 50 day simple moving average of $529.90 and a 200-day simple moving average of $539.42.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the prior year, the company posted $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on UTHR. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Toth Financial Advisory Corp boosted its stake in United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares during the period. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. WealthCollab LLC boosted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.